MedTrace Logo

Trial to Assess Efficacy and Safety of Lacosamide in Subjects With Osteoarthritis of the Knee

NCT00485472 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 194

Last updated 2017-08-28

Study results available
· View outcomes & findings →

Summary

The purpose of this trial is to evaluate the effectiveness, safety and tolerability of lacosamide (LCM) 400mg/day in treating the signs and symptoms of osteoarthritis of the knee.

Conditions

Interventions

DRUG

lacosamide

50 or 100mg tablet, 400mg daily, for 12 weeks

OTHER

Placebo

50 or 100mg tablet, 400mg daily, for 12 weeks, matched to Lacosamide

Sponsors & Collaborators

  • UCB Pharma

    lead INDUSTRY

Principal Investigators

  • UCB Clinical Trial Call Center · +1 877 822 9493 (UCB)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2007-11-30
Completion
2008-01-31

Countries

  • Czechia
  • Germany
  • Hungary
  • Poland
  • Romania
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00485472 on ClinicalTrials.gov